Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - topiramate, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; pregelatinised maize starch; magnesium stearate; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; iron oxide red; macrogol 400; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; purified water; industrial methylated spirit; ammonia - epilepsy. adults and children 2 years and over: as monotherapy in patients with newly diagnosed epilepsy;. for conversion to monotherapy in patients with epilepsy;as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. migraine. prophylaxis of migraine headache in adults.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - topiramate, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; pregelatinised maize starch; sodium starch glycollate; colloidal anhydrous silica; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; purified water; industrial methylated spirit; ammonia - epilepsy. adults and children 2 years and over: as monotherapy in patients with newly diagnosed epilepsy;. for conversion to monotherapy in patients with epilepsy;as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. migraine. prophylaxis of migraine headache in adults.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - tramadol hydrochloride -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - trandolapril, quantity: 4 mg - capsule - excipient ingredients: povidone; lactose monohydrate; sodium stearylfumarate; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide red; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - trandolapril, quantity: 2 mg - capsule - excipient ingredients: povidone; sodium stearylfumarate; maize starch; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - trandolapril, quantity: 1 mg - capsule - excipient ingredients: sodium stearylfumarate; lactose monohydrate; maize starch; povidone; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - trandolapril, quantity: 0.5 mg - capsule - excipient ingredients: lactose monohydrate; povidone; maize starch; sodium stearylfumarate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quinapril hydrochloride, quantity: 21.664 mg (equivalent: quinapril, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; magnesium stearate; colloidal anhydrous silica; povidone; calcium sulfate dihydrate; crospovidone; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quinapril hydrochloride, quantity: 5.416 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; povidone; calcium sulfate dihydrate; magnesium carbonate hydrate; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.